Does the media favor ATOS or ATRA?

In the previous week, Atara Biotherapeutics had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 3 mentions for Atara Biotherapeutics and 2 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 1.50 beat Atara Biotherapeutics' score of -0.07 indicating that Atossa Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ATOS or GANX more profitable?

Atossa Genetics' return on equity of -94.57% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -94.57% -78.80% Gain Therapeutics N/A -201.44% -136.24%

Does the media refer more to ATOS or GANX?

In the previous week, Atossa Genetics and Atossa Genetics both had 2 articles in the media. Atossa Genetics' average media sentiment score of 1.50 beat Gain Therapeutics' score of 0.53 indicating that Atossa Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ATOS or IBIO?

iBio has higher revenue and earnings than Atossa Genetics. iBio is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atossa Genetics N/A N/A -$34.77M -$3.21 N/A iBio $400K 174.50 -$18.38M -$0.58 N/A

Is ATOS or IBIO more profitable?

iBio's return on equity of -53.86% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -94.57% -78.80% iBio N/A -53.86% -46.48%

Does the media refer more to ATOS or IBIO?

In the previous week, iBio had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 3 mentions for iBio and 2 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 1.50 beat iBio's score of 0.60 indicating that Atossa Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive iBio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, CYPH or ATOS?

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cypherpunk Technologies N/A N/A $4.82M -$0.02 N/A Atossa Genetics N/A N/A -$34.77M -$3.21 N/A

Is CYPH or ATOS more profitable?

Cypherpunk Technologies' return on equity of -48.33% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Cypherpunk Technologies N/A -48.33% -42.21% Atossa Genetics N/A -94.57% -78.80%

Does the media refer more to CYPH or ATOS?

In the previous week, Atossa Genetics had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 2 mentions for Atossa Genetics and 1 mentions for Cypherpunk Technologies. Atossa Genetics' average media sentiment score of 1.50 beat Cypherpunk Technologies' score of 0.67 indicating that Atossa Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cypherpunk Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation & earnings, ATOS or OKYO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atossa Genetics N/A N/A -$34.77M -$3.21 N/A OKYO Pharma N/A N/A -$8.95M N/A N/A

Is ATOS or OKYO more profitable?

OKYO Pharma's return on equity of 0.00% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -94.57% -78.80% OKYO Pharma N/A N/A N/A

Atossa Genetics (ATOS) Competitors

$2.46 +0.10 (+4.03%)

As of 01:42 PM Eastern

Compare

ATOS vs. ATRA, GANX, IBIO, CYPH, and OKYO

Should you buy Atossa Genetics stock or one of its competitors? MarketBeat compares Atossa Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atossa Genetics include Atara Biotherapeutics (ATRA), Gain Therapeutics (GANX), iBio (IBIO), Cypherpunk Technologies (CYPH), and OKYO Pharma (OKYO). These companies are all part of the "biotechnology" industry.

How does Atossa Genetics compare to Atara Biotherapeutics?

Atossa Genetics (NASDAQ:ATOS) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Atossa Genetics presently has a consensus target price of $20.33, suggesting a potential upside of 728.24%. Atara Biotherapeutics has a consensus target price of $9.50, suggesting a potential upside of 10.47%. Given Atossa Genetics' stronger consensus rating and higher possible upside, equities analysts clearly believe Atossa Genetics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Atara Biotherapeutics has higher revenue and earnings than Atossa Genetics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
Atara Biotherapeutics	$23.14M	3.35	$32.69M	-$0.67	N/A

In the previous week, Atara Biotherapeutics had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 3 mentions for Atara Biotherapeutics and 2 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 1.50 beat Atara Biotherapeutics' score of -0.07 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Atossa Genetics has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market.

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Atossa Genetics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Atara Biotherapeutics' return on equity of -79.12% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-94.57%	-78.80%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

Summary

Atara Biotherapeutics beats Atossa Genetics on 8 of the 15 factors compared between the two stocks.

How does Atossa Genetics compare to Gain Therapeutics?

Atossa Genetics (NASDAQ:ATOS) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Atossa Genetics has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

In the previous week, Atossa Genetics and Atossa Genetics both had 2 articles in the media. Atossa Genetics' average media sentiment score of 1.50 beat Gain Therapeutics' score of 0.53 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Gain Therapeutics has higher revenue and earnings than Atossa Genetics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
Gain Therapeutics	$50K	1,531.99	-$20.16M	-$0.58	N/A

Atossa Genetics' return on equity of -94.57% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-94.57%	-78.80%
Gain Therapeutics	N/A	-201.44%	-136.24%

Atossa Genetics currently has a consensus price target of $20.33, suggesting a potential upside of 728.24%. Gain Therapeutics has a consensus price target of $7.50, suggesting a potential upside of 317.59%. Given Atossa Genetics' higher probable upside, equities research analysts plainly believe Atossa Genetics is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Atossa Genetics beats Gain Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Atossa Genetics compare to iBio?

Atossa Genetics (NASDAQ:ATOS) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Atossa Genetics presently has a consensus price target of $20.33, indicating a potential upside of 728.24%. iBio has a consensus price target of $5.00, indicating a potential upside of 255.87%. Given Atossa Genetics' higher probable upside, research analysts plainly believe Atossa Genetics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

iBio's return on equity of -53.86% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-94.57%	-78.80%
iBio	N/A	-53.86%	-46.48%

iBio has higher revenue and earnings than Atossa Genetics. iBio is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
iBio	$400K	174.50	-$18.38M	-$0.58	N/A

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by company insiders. Comparatively, 2.8% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, iBio had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 3 mentions for iBio and 2 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 1.50 beat iBio's score of 0.60 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
iBio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Atossa Genetics has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, iBio has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

Summary

iBio beats Atossa Genetics on 10 of the 15 factors compared between the two stocks.

How does Atossa Genetics compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and Atossa Genetics (NASDAQ:ATOS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Cypherpunk Technologies currently has a consensus target price of $0.90, indicating a potential upside of 34.33%. Atossa Genetics has a consensus target price of $20.33, indicating a potential upside of 728.24%. Given Atossa Genetics' higher probable upside, analysts clearly believe Atossa Genetics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

30.5% of Cypherpunk Technologies shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 3.5% of Cypherpunk Technologies shares are owned by insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Atossa Genetics had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 2 mentions for Atossa Genetics and 1 mentions for Cypherpunk Technologies. Atossa Genetics' average media sentiment score of 1.50 beat Cypherpunk Technologies' score of 0.67 indicating that Atossa Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cypherpunk Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cypherpunk Technologies' return on equity of -48.33% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Atossa Genetics	N/A	-94.57%	-78.80%

Cypherpunk Technologies has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market.

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A

Summary

Cypherpunk Technologies and Atossa Genetics tied by winning 7 of the 14 factors compared between the two stocks.

How does Atossa Genetics compare to OKYO Pharma?

Atossa Genetics (NASDAQ:ATOS) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by company insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

OKYO Pharma's return on equity of 0.00% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-94.57%	-78.80%
OKYO Pharma	N/A	N/A	N/A

Atossa Genetics currently has a consensus price target of $20.33, indicating a potential upside of 728.24%. OKYO Pharma has a consensus price target of $5.67, indicating a potential upside of 264.42%. Given Atossa Genetics' higher possible upside, analysts clearly believe Atossa Genetics is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Atossa Genetics has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market.

In the previous week, Atossa Genetics had 2 more articles in the media than OKYO Pharma. MarketBeat recorded 2 mentions for Atossa Genetics and 0 mentions for OKYO Pharma. Atossa Genetics' average media sentiment score of 1.50 beat OKYO Pharma's score of 0.00 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Overall Sentiment
Atossa Genetics	Very Positive
OKYO Pharma	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A

Summary

Atossa Genetics and OKYO Pharma tied by winning 5 of the 10 factors compared between the two stocks.

Get Atossa Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATOS vs. The Competition

Export

Metric	Atossa Genetics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$21.14M	$3.72B	$7.04B	$12.92B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.76	9.08	269.97	24.82
Price / Sales	N/A	1,268.38	650.66	108.09
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.54	17.65	11.26	6.44
Net Income	-$34.77M	-$13.25M	$3.45B	$347.27M
7 Day Performance	13.13%	5.33%	3.62%	2.55%
1 Month Performance	3.59%	-1.83%	-0.56%	-1.02%
1 Year Performance	-79.20%	61.05%	77.38%	23.33%

Atossa Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATOS Atossa Genetics	2.5803 of 5 stars	$2.46 +4.0%	$20.33 +728.2%	-80.0%	$21.14M	N/A	N/A	8	Positive News Earnings Report Gap Down
ATRA Atara Biotherapeutics	1.3123 of 5 stars	$8.70 +1.8%	$9.50 +9.2%	-22.8%	$78.39M	$23.14M	N/A	330	News Coverage Analyst Downgrade
GANX Gain Therapeutics	2.2437 of 5 stars	$1.74 -0.9%	$7.50 +332.3%	+23.0%	$74.00M	$50K	N/A	20	News Coverage Upcoming Earnings
IBIO iBio	2.5299 of 5 stars	$1.48 +3.9%	$5.00 +239.0%	N/A	$73.28M	$400K	N/A	100	Gap Up
CYPH Cypherpunk Technologies	2.4647 of 5 stars	$0.67 +5.8%	$0.90 +33.6%	+118.2%	$71.74M	N/A	N/A	40	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATOS) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atossa Genetics (ATOS) Competitors

ATOS vs. ATRA, GANX, IBIO, CYPH, and OKYO

How does Atossa Genetics compare to Atara Biotherapeutics?

Summary

How does Atossa Genetics compare to Gain Therapeutics?

Summary

How does Atossa Genetics compare to iBio?

Summary

How does Atossa Genetics compare to Cypherpunk Technologies?

Summary

How does Atossa Genetics compare to OKYO Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATOS vs. The Competition

Atossa Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atossa Genetics (ATOS) Competitors

ATOS vs. ATRA, GANX, IBIO, CYPH, and OKYO

How does Atossa Genetics compare to Atara Biotherapeutics?

Do analysts recommend ATOS or ATRA?

Which has stronger valuation & earnings, ATOS or ATRA?

Does the media favor ATOS or ATRA?

Which has more volatility & risk, ATOS or ATRA?

Do institutionals & insiders hold more shares of ATOS or ATRA?

Is ATOS or ATRA more profitable?

Summary

How does Atossa Genetics compare to Gain Therapeutics?

Which has more risk and volatility, ATOS or GANX?

Does the media refer more to ATOS or GANX?

Do insiders & institutionals hold more shares of ATOS or GANX?

Which has better earnings and valuation, ATOS or GANX?

Is ATOS or GANX more profitable?

Do analysts recommend ATOS or GANX?

Summary

How does Atossa Genetics compare to iBio?

Do analysts recommend ATOS or IBIO?

Is ATOS or IBIO more profitable?

Which has preferable valuation & earnings, ATOS or IBIO?

Do institutionals & insiders believe in ATOS or IBIO?

Does the media refer more to ATOS or IBIO?

Which has more volatility & risk, ATOS or IBIO?

Summary

How does Atossa Genetics compare to Cypherpunk Technologies?

Do analysts prefer CYPH or ATOS?

Do insiders & institutionals believe in CYPH or ATOS?

Does the media refer more to CYPH or ATOS?

Is CYPH or ATOS more profitable?

Which has more risk and volatility, CYPH or ATOS?

Which has stronger valuation and earnings, CYPH or ATOS?

Summary

How does Atossa Genetics compare to OKYO Pharma?

Do insiders and institutionals believe in ATOS or OKYO?

Is ATOS or OKYO more profitable?

Do analysts rate ATOS or OKYO?

Which has more volatility & risk, ATOS or OKYO?

Does the media refer more to ATOS or OKYO?

Which has stronger valuation & earnings, ATOS or OKYO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATOS vs. The Competition

Atossa Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools